Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.
You may also be interested in...
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical
Synta provided one-year follow-up data for its Phase IIb/III trial testing ganetespib in NSCLC and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
Synta’s Ganetespib Could Break The Hsp90i Curse
If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.